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OBJECTIVE—Posttranslational prenylation (e.g., farnesylation)
of small G-proteins is felt to be requisite for cytoskeletal remod-
eling and fusion of secretory vesicles with the plasma membrane.
Here, we investigated roles of protein farnesylation in the
signaling steps involved in Raf-1/extracellular signal–related ki-
nase (ERK1/2) signaling pathway in glucose-induced Rac1 acti-
vation and insulin secretion in the pancreatic -cell.
RESEARCH DESIGN AND METHODS—These studies were
carried out in INS 832/13 cells and normal rat islets. Molecular
biological (e.g., overexpression or small interfering RNA
[siRNA]–mediated knockdown) and pharmacologic approaches
were used to determine roles for farnesylation in glucose-
mediated activation of ERK1/2, Rac1, and insulin secretion.
Activation of ERK1/2 was determined by Western blotting. Rac1
activation (i.e., Rac1.GTP) was quantitated by p21-activated
kinase pull-down assay. Insulin release was quantitated by en-
zyme-linked immunosorbent assay.
RESULTS—Coprovision of structure-speciﬁc inhibitors of far-
nesyl transferase (FTase; e.g., FTI-277 or FTI-2628) or siRNA-
mediated knockdown of FTase -subunit resulted in a signiﬁcant
inhibition of glucose-stimulated ERK1/2 and Rac1 activation and
insulin secretion. Pharmacologic inhibition of Raf-1 kinase using
GW-5074 markedly reduced the stimulatory effects of glucose on
ERK1/2 phosphorylation, Rac1 activation, and insulin secretion,
suggesting that Raf-1 kinase activation may be upstream to
ERK1/2 and Rac1 activation leading to glucose-induced insulin
release. Lastly, siRNA-mediated silencing of endogenous expres-
sion of ERK1/2 markedly attenuated glucose-induced Rac1 acti-
vation and insulin secretion.
CONCLUSIONS—Together, our ﬁndings provide the ﬁrst evi-
dence of a role for protein farnesylation in glucose-mediated
regulation of the Raf/ERK signaling pathway culminating in the
activation of Rac1, which has been shown to be necessary for
cytoskeletal reorganization and exocytotic secretion of insulin.
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n the majority of cells, transduction of extracellular
signals involves ligand binding to a receptor, often
followed by the activation of one (or more) G-
proteins and their respective effector proteins. The
pancreatic islet -cell is unusual in that regard because
glucose, the major physiological insulin secretagogue,
lacks an extracellular receptor. Instead, metabolic and
cationic events of glucose metabolism are implicated in
insulin secretion (1–4). Changes in calcium concentration
not only initiate insulin release, but also regulate protein
kinases culminating in insulin secretion (1–5). In addition
to calcium-dependent protein kinases, several other ki-
nases, including the mitogen-activated protein kinases
(e.g., extracellular signal-regulated kinases [ERK1/2]) have
been identiﬁed and characterized in the pancreatic islet
-cell (5–7). Emerging evidence also suggests G-protein–
mediated regulation of protein kinases in multiple cell
types, including the islet -cell. For example, p21-activated
kinase (PAK1), and Raf-1 kinase are regulated by Cdc42/
Rac1 (8,9) and H-Ras (10,11), respectively. Furthermore,
speciﬁc regulatory factors of small G-proteins (e.g.,
guanosine diphosphate dissociation inhibitor) are modu-
lated by phosphorylation-dephosphorylation (12).
The majority of small G-proteins (e.g., Cdc42, Rac1, and
H-Ras) undergo requisite posttranslational prenylation at
their COOH-terminal cysteine residues, which control
their intracellular trafﬁcking and localization to facilitate
optimal interactions with their respective effector proteins
(13–15). Protein prenylation involves incorporation of
either farnesyl pyrophosphate, a 15-carbon derivative of
mevalonic acid, by the farnesyl transferases (FTases), or
geranylgeranyl pyrophosphate, a 20-carbon derivative
of mevalonic acid, by the geranylgeranyl transferase
(GGTase) into the COOH-terminal cysteine (13–15). At
least three distinct prenylating enzymes have been de-
scribed (16–18). The FTase and GGTase-I are often re-
ferred to as CAAX prenyl transferases because their
substrate proteins share a conserved CAAX motif at their
COOH-terminal region. The GGTase-II prenylates the Rab
subfamily of proteins at a different motif and hence is
termed a non–CAAX prenyl transferases. FTase, GGTase-I,
and GGTase-II are heterodimeric (i.e., consisting of - and
-subunits). Both FTase and GGTase-I share a common
-subunit, but different -subunits. The -subunit is the
regulatory subunit, whereas the -subunit confers sub-
strate speciﬁcity. Goalstone et al. have demonstrated that
the -subunit of FTase/GGTase undergoes phosphoryla-
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sulting in the prenylation of G-proteins (19). Using phar-
macologic inhibitors of prenylation, earlier studies have
demonstrated regulatory roles for small G-proteins in
insulin secretion in islet -cells (15,20–23); these observa-
tions were further conﬁrmed by molecular biological
approaches involving a dominant-negative mutant of
FTase/GGTase-I  subunit (23).
Evidence from multiple laboratories implicates the mi-
togen-activated protein kinase signaling pathway in the
regulation of islet -cell function (6,24–28). Some of these
investigations have implicated roles for small G-proteins in
glucose- or growth factor–induced activation of ERK1/2 in
-cells leading to insulin gene transcription. The current
study is aimed at verifying our recently proposed model
implicating protein farnesylation in glucose-mediated ac-
tivation of ERK1/2 and insulin secretion in the pancreatic
-cell (14). Using pharmacologic and molecular biological
approaches, we present the ﬁrst evidence to suggest that
glucose-induced Rac1 activation and insulin secretion
require the intermediacy of a H-Ras–independent, but
Raf-1/ERK1/2–dependent signaling step.
RESEARCH DESIGN AND METHODS
Materials. GW-5074 was from Biomol Research Laboratories (Plymouth
Meeting, PA). FTI-277 and FTI-2628 were from Calbiochem (San Diego, CA).
Mastoparan was purchased from Sigma (St. Louis, MO). Antisera against
H-Ras and Raf-1 were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). The rat insulin ELISA kit was from American Laboratory Products
(Windham, NH). Antibodies against phospho-p44/42 ERK kinase (Thr202/
Tyr204) and total p44/42 ERK kinase were from Cell Signaling Technology
(Danvers, MA). A pool of two target-speciﬁc 20- to 25-nucleotide small
interfering RNAs (siRNAs) designed to knock down the expression of FTase
-subunit and scrambled siRNA (negative control) were from Applied Biosys-
tems, Ambion (Austin, TX).
Insulin-secreting cells. INS 832/13 cells (provided by Dr. Chris Newgard)
were propagated as described in (29). Pancreatic islets from male Sprague-
Dawley rats (200–250 g body wt; Harlan Laboratories) were isolated by the
collagenase digestion method (29,30).
siRNA-mediated knockdown of H-Ras or the -subunit of FTase. Endog-
enous H-Ras or FTase -subunit expression was depleted by transfecting cells
using siRNA at a ﬁnal concentration of 100 nmol/l using HiPerfect transfection
reagent (Qiagen, Valencia, CA). To assess the speciﬁcity of RNA interference
method, cells were transfected (as above) with nontargeting RNA; this
includes at least four nucleotide mismatches with all known mouse, rat, and
human gene (i.e., scrambled siRNA) duplexes (Santa Cruz Biotechnology).
Efﬁciency of H-Ras or FTase -subunit knockdown was determined by
Western blot analysis.
Transfection of Raf-1 kinase mutants. INS 832/13 cells were subcultured at
70–80% conﬂuence and transfected using Effectene (Qiagen), with 0.2 go f
plasmid DNA constructs against Raf-1 (mock, vector, wild type, or constitu-
tively active; BXB; provided by Dr. Melanie Cobb) per well of a 24-well plate.
The cells were used for insulin secretion studies or for Western blotting
studies.
Quantitation of glucose-stimulated insulin secretion. INS 832/13 cells or
islets, treated with either FTase inhibitors or Raf-1 inhibitor or transfected
with H-Ras siRNAs or wild-type and constitutively active Raf-1 (BXB) mutants
were further incubated in the presence of either low (2.5 mmol/l) or high (20
mmol/l) glucose for 30 min at 37°C in the continuous absence or presence of
inhibitors as indicated in the text. Insulin released into the medium was
quantitated by enzyme-linked immunosorbent assay (ELISA) (23,29).
siRNA mediated knockdown of the ERK1 and ERK2. Endogenous expres-
sion of either ERK1 or ERK2 was speciﬁcally silenced in INS 832/13 cells using
siRNA. A pool of three target-speciﬁc 19- to 25-nucleotide siRNAs designed to
knockdown ERK1 and ERK2 gene was obtained from Santa Cruz Biotechnol-
ogy. In brief, cells were seeded and grown in 24-well plates in appropriate
growth medium to achieve 40–50% conﬂuence. Cells were transfected with
ERK1 and/or ERK2 siRNA or scrambled siRNA (as a negative control) using
HiPerfect reagent according to the manufacturer’s instructions. The efﬁciency
of the siRNA transfection and ERK1/2 knockdown was veriﬁed by Western
blotting.
ERK1/2 phosphorylation assay. INS 832/13 cells or islets, either treated
with pharmacologic inhibitors or transfected with speciﬁc siRNAs or Raf-1
mutants were incubated in the presence of either low (2.5 mmol/l) or high (20
mmol/l) glucose for 30 min at 37°C. After this, the cells were homogenized in
a buffer consisting of 20 mmol/l Tris (pH 7.5), 150 mmol/l NaCl, 1 mmol/l
EDTA, 1 mmol/l EGTA, 1% Triton X-100, 2.5 mmol/l sodium pyrophosphate, 1
mmol/l -glycerophosphate, 1 mmol/l Na3VO4,1g/ml leupeptin, and 1 mmol/l
phenylmethylsulfonyl ﬂuoride. Relative abundance of total and phospho-
ERK1/2 was determined by Western blotting.
Quantitation of glucose-stimulated Rac1 activation. The degree of Rac1
activation (i.e., GTP-bound form) was determined by the PAK/PBD (p21-
activated kinase/p21-binding domain) pull-down assay as described in
(23,29,31). Relative abundance of Rac1 in the pull-down samples was quanti-
tated by densitometry of Rac1 bands identiﬁed by Western blotting.
Statistical analyses. The statistical signiﬁcance of the differences between
the experimental conditions was determined by Student t test. P values less
than 0.05 were considered signiﬁcant.
RESULTS
Glucose and mastoparan augment ERK1/2 phosphor-
ylation in pancreatic -cells. Data in Fig. 1 indicate that
incubation of INS 832/13 cells with a stimulatory concen-
tration of glucose (20 mmol/l) led to nearly two-fold
increase in the phosphorylation of ERK1/2. Moreover,
incubation of these cells with mastoparan (Mas), a global
activator of G-proteins (32) and insulin secretion (7,21,33–
FIG. 1. Stimulatory concentrations of glucose or mastoparan, a global
activator of G-proteins, potentiate ERK1/2 phosphorylation in INS
832/13. A: INS 832/13 cells were cultured overnight in low-glucose–
containing medium and were further incubated in the presence of low
(2.5 mmol/l) or high (20 mmol/l) glucose or Mas (30 mol/l) for 30 min
at 37°C. Lysates of cells from above experimental conditions were
separated by SDS-PAGE followed by transfer onto a nitrocellulose
membrane. The membranes were then blocked and incubated with
anti–phosphorylated ERK1/2 (p-ERK1/2) followed by incubation with
horseradish peroxidase (HRP)–conjugated secondary antibody. The
same blots were then stripped and reprobed with ERK1/2 antibody. A
representative blot from three experiments is shown here. B: The
relative intensities of p-ERK1/2:total ERK1/2 ratio quantitated by
densitometry. Data are expressed as fold increase over basal glucose
and are means  SEM from three experiments. *P < 0.001 vs. 2.5
mmol/l glucose and **P < 0.001 vs. 20 mmol/l glucose.
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pronounced effects of Mas on ERK1/2 phosphorylation
suggested that one (or more) G-proteins may be involved
in this signaling cascade. To further assess roles of G-
proteins in the sequence of events leading to glucose-
induced ERK1/2 phosphorylation and insulin secretion, we
undertook a pharmacologic approach to speciﬁcally in-
hibit the G-protein activation via attenuating the -cell
FTases through the use of site-speciﬁc inhibitors of
farnesylation.
FTase inhibition markedly reduces glucose-induced
activation of ERK1/2 and insulin release in pancre-
atic -cells. Data described in Fig. 2A and B demonstrate
that incubation of INS 832/13 cells with a stimulatory
concentration of glucose (20 mmol/l) leads to a signiﬁcant
increase in ERK1/2 phosphorylation, data compatible with
those provided in Fig. 1. FTI-277, a known inhibitor of
protein farnesylation, totally abrogated the effect of glu-
cose to stimulate ERK1/2 activation without signiﬁcantly
affecting the basal phosphorylation of ERK1/2 seen in the
presence of 2.5 mmol/l glucose. Under these conditions,
FTI-277 also inhibited glucose-stimulated insulin secretion
(GSIS) signiﬁcantly without exerting any effects on basal
insulin secretion (Fig. 2C). In a manner akin to INS 832/13
cells (Fig. 2), glucose signiﬁcantly stimulated the phos-
phorylation of ERK1/2 in isolated rat islets (Fig. 3A) and
such a signaling step was sensitive to FTase inhibition.
FTI-277 completely inhibited glucose-induced activation of
ERK1/2 without signiﬁcantly affecting the basal phosphor-
ylation (Fig. 3A). Data in Fig. 3B further conﬁrm the
inhibitory effects of FTI-277 on GSIS in normal rat islets.
Moreover, FTI-2628, another structure-speciﬁc FTase in-
hibitor, completely inhibited GSIS in normal rat islets.
Together, data in Figs. 2 and 3 implicate a role for protein
farnesylation in glucose-induced activation of ERK1/2
phosphorylation and insulin secretion in INS 832/13 cells
and isolated rat islets.
siRNA-mediated knockdown of FTase -subunit in-
hibits glucose-induced ERK1/2 activation and insulin
secretion. As stated above, FTase and GGTase-I share a
common -subunit. The -subunits, which confer sub-
strate speciﬁcity, are different however. To further deter-
mine whether glucose-induced activation of ERK1/2 and
insulin secretion require farnesylation, we depleted the
expression of endogenous FTase -subunit using siRNA
methodology and then quantitated glucose-mediated acti-
vation of ERK1/2 and GSIS in INS 832/13 cells. Data
described in Fig. 4A indicate 60% inhibition in the
expression of FTase  under our current experimental
conditions. Under these conditions, the ability of glucose
FIG. 2. FTI-277, a speciﬁc inhibitor of protein farnesylation, markedly attenuates ERK1/2 phosphorylation and insulin secretion in INS 832/13
-cells. A: INS 832/13 cells were treated with either diluent alone or FTI-277 (5 mol/l) as indicated in the ﬁgure and cultured overnight in
low-glucose media. Cells were further incubated in the presence of either low (2.5 mmol/l) or high (20 mmol/l) glucose for 30 min at 37°C in the
continuous presence of either diluent alone or FTI-277. Cell lysates were separated by SDS-PAGE followed by transfer to a nitrocellulose
membrane. The membranes were then blocked and incubated with anti–p-ERK1/2 followed by incubation with HRP-conjugated secondary
antibody. The same blots were then stripped and reprobed with ERK1/2 antibody. A representative blot from three experiments is shown here.
B: The relative intensities of p-ERK1/2:total ERK1/2 ratio quantitated by densitometry. Data are expressed as fold increase over basal glucose
and are means  SEM from three experiments. *P < 0.001 vs. 2.5 mmol/l glucose and **P < 0.001 vs. 20 mmol/l glucose in the absence of FTI-277.
C: INS 832/13 cells were treated with either diluent alone or FTI-277 (5 mol/l) and cultured overnight in low-glucose media. Cells were further
incubated in the presence of either low (2.5 mmol/l) or high (20 mmol/l) glucose for 30 min at 37°C in the continuous presence of either diluent
alone or FTI-277. Insulin released into the medium was quantitated by ELISA. The data are expressed as percentage of basal and are means 
SEM from three independent experiments. *P < 0.05 vs. 2.5 mmol/l glucose and **P < 0.05 vs. 20 mmol/l glucose in the absence of FTI-277.
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ished (Fig. 4B), ﬁndings in line with our pharmacologic
data (Figs. 2 and 3). Moreover, we noticed a marked
inhibition in GSIS in FTase -siRNA–transfected cells (Fig.
4C). Based on these data, we conclude that a protein
farnesylation–sensitive step is necessary for glucose to
promote the activation of ERK1/2 phosphorylation and
insulin secretion.
siRNA-mediated knockdown of H-Ras expression
elicits no signiﬁcant effects on glucose-induced acti-
vation of ERK1/2 and insulin secretion in pancreatic
-cells. It is widely felt that regulation of ERK1/2 involves
the sequential activation of Ras/Raf-1 kinase signaling
cascade. Because our data indicated that glucose-medi-
ated effects on ERK1/2 phosphorylation require a farnesy-
lation step, and because Ras is a farnesylated protein, we
investigated roles of H-Ras in this signaling cascade. To
address this, we quantitated glucose-induced ERK1/2 acti-
vation and insulin secretion in INS 832/13 cells in which
H-Ras expression was knocked down by the siRNA ap-
proach. Data in Fig. 5A and B suggest nearly 50% knock-
down of H-Ras expression in INS 832/13 cells under our
current experimental conditions. Data in Fig. 5C and D
indicated no signiﬁcant effects of H-Ras depletion on
glucose-induced ERK1/2 phosphorylation in these cells. In
addition, we observed that GSIS in INS 832/13 cells was
resistant to H-Ras depletion (Fig. 5E). These ﬁndings
indicate that H-Ras plays a minimal regulatory role(s), if
any, in signaling events leading to glucose-induced activa-
tion of ERK1/2 phosphorylation and insulin secretion.
Activation of Raf-1 kinase is necessary for glucose-
mediated activation of ERK1/2 and insulin secretion
in pancreatic -cells. We next examined whether Raf-1
kinase activation represents a regulatory step in glucose-
induced activation of ERK1/2 phosphorylation and insulin
secretion because it has been implicated in the regulation
of members of mitogen-activated protein kinase family in
multiple cell types including the pancreatic -cell (6,24–
28,37–41). We also examined regulation by Raf-1 kinase
pathway of GSIS under the conditions in which it regulates
ERK1/2 phosphorylation. In the ﬁrst series of studies, we
determined the effects of GW-5074, a known inhibitor of
Raf-1 kinase, on glucose-mediated activation of ERK1/2
phosphorylation and insulin secretion. Data in Fig. 6A and
B demonstrated a near complete inhibition of glucose-
induced ERK1/2 activation by GW-5074. We also observed
that GW-5074 inhibitor abolished GSIS under the same
conditions that it inhibited ERK1/2 phosphorylation (Fig.
6C). It should be noted that, unlike GSIS, KCl-stimulated
insulin secretion was completely resistant to the inhibitory
effects of GW-5074 (Fig. 6D); these data rule out potential
nonspeciﬁc effects of the inhibitor, and afford further
support to potential involvement of the Raf-1/ERK1/2
pathway in cytoskeletal reorganization leading to GSIS.
In the second approach, we investigated whether over-
expression of a constitutively active mutant of Raf-1
potentiates glucose-induced ERK1/2 phosphorylation and
insulin secretion. To address this, INS 832/13 cells were
transfected with either wild-type Raf-1 or a constitutively
active mutant of Raf-1 (BXB/Raf-1). Data in Fig. 6E repre-
sent a Western blot, illustrating a signiﬁcant glucose-
mediated activation of ERK1/2 in INS 832/13 cells
transfected with wild-type or the BXB/Raf-1–transfected
cells. Albeit variable, we noticed a modest increase in
ERK1/2 phosphorylation under basal glucose conditions in
cells expressing either the wild-type or constitutively
active Raf-1 mutants (Fig. 6E and F). No signiﬁcant
potentiation of glucose-induced ERK1/2 phosphorylation
was seen in cells expressing either the wild-type or the
constitutively active Raf-1 kinase mutant (Fig. 6E and F).
FIG. 3. Inhibition of protein farnesylation leads to reduction of
glucose-stimulated ERK1/2 phosphorylation and insulin secretion in
normal rat islets. A: Normal rat islets were cultured overnight in
low-glucose–containing medium in the presence of diluent alone or
FTI-277 (5 mol/l). The next morning, they were further incubated in
the presence of either low (2.5 mmol/l) or high (20 mmol/l) glucose for
30 min at 37°C in the continuous presence of FTI-277 or diluent. Islet
lysates were separated by SDS-PAGE followed by transfer onto a
nitrocellulose membrane. The membranes were then blocked and
incubated with anti–p-ERK1/2 followed by incubation with HRP-conju-
gated secondary antibody. The relative intensities of p-ERK1/2:total
ERK1/2 ratio were plotted based on the densitometric scan. Data are
expressed as fold increase and are means  SEM from three experi-
ments. *P < 0.001 vs. 2.5 mmol/l glucose and **P < 0.001 vs. 20 mmol/l
glucose in the absence of FTI-277. B: Normal rat islets were cultured
overnight in low-glucose–containing medium in the presence of diluent
alone. FTI-277 (5 mol/l), or FTI-2628 (10 mol/l) as indicated in the
ﬁgure. Islet lysates were further incubated in the presence of either
low (2.5 mmol/l) or high (20 mmol/l) glucose for 30 min at 37°C in the
continuous presence of either FTI-277, FTI-2628, or diluent. Insulin
released into the medium was quantitated by ELISA. The data are
expressed as percentage of basal and are means  SEM from three
independent experiments. *P < 0.05 vs. 2.5 mmol/l glucose, **P < 0.05
vs. 20 mmol/l glucose alone.
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cells transfected with the BXB/Raf-1 mutant compared
with vector or wild-type Raf-1–transfected cells (Fig. 6G).
Together, data presented in Fig. 6A–G support our hypoth-
esis that a farnesylation-requiring, Ras-independent, but
Raf-1–dependent signaling event is essential for glucose-
mediated regulation of ERK1/2 activation and insulin
release in isolated -cells (see below).
FTase and Raf-1 kinase activation steps are neces-
sary for glucose-induced Rac1 activation in -cells.
Published evidence (8,14,23,39,42) implicates activation of
Rho subfamily small G-proteins (e.g., Rac1) in GSIS. Here,
we investigated glucose-induced activation of Rac1 (i.e.,
Rac1-GTP) in control cells and in cells in which Raf-1
kinase activation is negated via pharmacologic inhibition
using GW-5074. Stimulatory concentrations of glucose
signiﬁcantly increased the relative abundance of GTP-
bound Rac1, which was decreased signiﬁcantly in cells
incubated with GW-5074 (Fig. 7A and B). It should also be
noted that a modest, but signiﬁcant increase in the activa-
tion of Rac1 was seen in GW-5074–treated cells under
low-glucose treatment conditions compared with cognate
cellular preparations exposed to diluent alone. Total
Rac1 did not change under these conditions (Fig. 7A). In
a preliminary study, we also observed similar inhibitory
effects by GW-5074 on glucose-induced activation of
Rac1 in rodent islets (159% of control in high-glucose–
treated cells in the absence of GW-5074 vs. 72% of
control in the presence of GW-5074 and high glucose).
However, as in the case of INS 832/13 cells, GW-5074
increased Rac1 activation under basal conditions (data
not shown).
To further examine a role for FTase in this signaling
cascade, we quantitated glucose-induced activation of
Rac1 in INS 832/13 cells in the absence or presence of
FTI-277. Data in Fig. 7C suggested a signiﬁcant reduc-
tion in glucose-induced Rac1 activation after FTase
inhibition. In a manner akin to GW-5074 (Fig. 7B), a
consistent increase in Rac1 activation was noticed in
FTI-277–treated cells under low-glucose conditions. To-
gether, these data implicate that a FTase/Raf-1 kinase–
sensitive signaling mechanism(s) may underlie glucose-
induced activation of Rac1. It is important to note that
the inhibitory effects of GW-5074 on glucose signaling
pathway (i.e., ERK1/2 activation, Rac1 activation, and
insulin secretion) were not due to its cytotoxicity
because no signiﬁcant effects of this compound on the
metabolic cell viability of INS 832/13 cells were noticed.
The cell viability rates represented 103.70  2.12% of
control in GW-5074 (10 mol/l)–treated cells (not signif-
icant vs. diluent-treated cells; n  3).
ERK1/2 activation is necessary for Rac1 activation
and GSIS. To conclusively determine regulatory role for
ERK1/2 in glucose-induced Rac1 activation and associated
insulin secretion, we quantitated these two events in INS
832/13 cells in which ERK1/2 expression was knocked
down using siRNA-ERK1 or siRNA-ERK2, singly or in
combination. Data depicted in Fig. 8A and B suggested a
marked reduction in the expression of these proteins after
transfection with speciﬁc siRNA, but not scrambled
siRNA. Transfection of either siRNA-ERK1 or siRNA-ERK2
(100 nmol/l each) or a combination of both (at 50 nmol/l
each) markedly attenuated GSIS compared with the
scrambled siRNA–transfected cells (Fig. 8C). In support of
our original hypothesis and compatible with data de-
scribed above, we also noticed complete inhibition of
glucose-induced activation of Rac1 in ERK1/2-depleted
cells.
FIG. 4. siRNA-mediated depletion of the -subunit of FTase leads to inhibition of glucose-stimulated ERK1/2 phosphorylation and insulin
secretion in INS 832/13 cells. A: INS 832/13 cells were transfected with either scrambled siRNA or siRNA speciﬁc for FTase -subunit as described
in the RESEARCH DESIGN AND METHODS section. Expression of the FTase -subunit was veriﬁed by Western blotting. A representative blot from three
independent studies yielding similar results is provided here. B: Transfected cells were further incubated in the presence of either low (2.5
mmol/l) or high (20 mmol/l) glucose for 30 min at 37°C. Lysates from these cells were separated by SDS-PAGE followed by transfer onto a
nitrocellulose membrane. The membranes were then blocked and incubated with anti–p-ERK1/2 followed by incubation with HRP-conjugated
secondary antibody. A representative blot from three experiments yielding comparable data is shown here. C: Transfected cells were incubated
with either low (2.5 mmol/l) or high (20 mmol/l) glucose for 30 min at 37°C. Insulin released into the medium was quantitated by ELISA. The data
are expressed as percentage of basal and are means  SEM from eight independent determinations. *P < 0.05 for scrambled low vs. high glucose,
**P < 0.05 for siRNA-FTase -subunit low vs. high glucose.
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The overall objective of this study was to investigate the
regulatory roles of protein farnesylation in the signaling
events leading to glucose-induced ERK1/2 activation and
insulin secretion in pancreatic -cells. Salient ﬁndings of
this study are 1) coprovision of structure-speciﬁc inhibi-
tors or siRNA-mediated knockdown of FTase -subunit
endogenous to the -cell resulted in a signiﬁcant inhibition
of glucose-stimulated ERK1/2 activation and insulin secre-
tion; 2) siRNA-mediated silencing of ERK1/2 resulted in a
signiﬁcant reduction in glucose-induced Rac1 activation
and GSIS, suggesting a pivotal role for ERK1/2 in this
signaling event; and 3) pharmacologic inhibition of Raf-1
kinase markedly reduced the stimulatory effects of glucose
on ERK1/2 phosphorylation, Rac1 activation, and insulin
secretion, suggesting that Raf-1 kinase activation may be
upstream to ERK1/2 and Rac1 activation resulting in GSIS.
Taken together, our data provide the ﬁrst evidence for the
involvement of Raf-1/ERK1/2/Rac1 signaling pathway in
GSIS.
A growing body of recent evidence suggests that the
stimulatory effects of glucose and other secretagogues on
ERK1/2 activation may involve G-protein activation. For
example, glucose-dependent insulinotropic peptide was
shown to activate ERK via a cAMP-dependent mecha-
nism(s) involving monomeric (e.g., Rap1) but not trimeric
(24) G-proteins. In MIN6 cells, glucagon-like peptide 1
(GLP-1) stimulated ERK activity by a mechanism involving
protein kinase A– and calmodulin kinase–dependent, but
Rap1-, Ras-, or Raf-1–independent, signaling steps (27).
FIG. 5. Glucose continues to stimulate ERK1/2 phosphorylation and insulin secretion in cells in which H-Ras expression was negated using H-Ras
siRNA. A: INS 832/13 cells were transfected with mock, scrambled siRNA, or H-Ras siRNA at a ﬁnal concentration of 100 nmol/l using HiPerfect
transfection reagent. Lysates from the above cellular preparations were separated by SDS-PAGE, transferred onto nitrocellulose membrane, and
probed with an antibody raised against H-Ras followed by incubation with HRP-conjugated secondary antibody. The same blots were then stripped
and reprobed with actin antibody. A representative blot from three experiments is shown here. B: The relative intensities of actin:H-Ras ratio
quantitated by densitometry. Data are expressed as means  SEM from three experiments. *P < 0.001 vs. mock- or scrambled siRNA–transfected
cells. C: INS-1 832/13 cells were transfected with mock, scrambled siRNA, or H-Ras siRNA at a ﬁnal concentration of 100 nmol/l using HiPerfect
transfection reagent and cultured overnight in low-glucose media. Cells were further incubated in the presence of either low (2.5 mmol/l) or high
(20 mmol/l) glucose for 30 min at 37°C. Cell lysates were separated by SDS-PAGE followed by transfer onto a nitrocellulose membrane.
The membranes were then blocked and incubated with anti–p-ERK1/2 followed by incubation with HRP-conjugated secondary antibody. The same
blots were then stripped and reprobed with ERK1/2 antibody. A representative blot from three experiments is shown here. D: The rela-
tive intensities of p-ERK1/2:total ERK1/2 ratio quantitated by densitometry. Data are expressed as fold increase and are means  SEM from three
experiments. *P < 0.001 vs. 2.5 mmol/l glucose-treated cells transfected with either mock, scrambled siRNA, or H-Ras siRNA. E: INS 832/13 cells
were transfected with mock, scrambled siRNA, or H-Ras siRNA at a ﬁnal concentration of 100 nmol/l using HiPerfect transfection reagent and
cultured overnight in low-glucose media. The cells were further incubated in the presence of either low (2.5 mmol/l) or high (20 mmol/l) glucose
for 30 min at 37°C. Insulin released into the medium was quantitated by ELISA. Data, which are expressed as percentage of basal, are means 
SEM from three experiments. *P < 0.01 vs. 2.5 mmol/l glucose-treated cells. NS, not signiﬁcant vs. mock- or scrambled siRNA–transfected cells
treated with stimulatory glucose concentrations.
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glucose and GLP-1 in INS-1 cells. Furthermore, inactive
mutants of Ras or Raf-1 markedly reduced glucose-in-
duced activation of ERK, suggesting important regulatory
roles for the Ras/Raf-1 signaling steps in this signaling
cascade. In contrast, studies by Briaud et al. demonstrated
inhibition of IGF-1–mediated, but not glucose-induced,
activation of ERK in INS-1 cells after overexpression of a
dominant-negative Ras mutant (25). The underlying rea-
sons for these differences between the two studies on the
regulatory roles of Ras in glucose-mediated effects on
ERK1/2 activation remain to be determined. Lastly, poten-
tial regulation of a Rap-1/B-Raf–, but not Ras/Raf-1–,
sensitive mechanism(s) in GLP-1 and glucose-mediated
activation of ERK was reported in human islets (26).
Despite the uncertainty about the identity of the G-
FIG. 6. Raf-1 kinase activation is necessary for glucose-induced ERK1/2 phosphorylation and insulin secretion in INS 832/13 -cells. A: INS 832/13
cells were treated with either diluent alone or GW-5074 (10 mol/l) as indicated in the ﬁgure, and cultured overnight in low-glucose media.
The cells were further incubated in the presence of either low (2.5 mmol/l) or high (20 mmol/l) glucose for 30 min at 37°C in the continuous
presence of either GW-5074 or diluent. Cell lysates were then separated by SDS-PAGE followed by transfer onto a nitrocellulose membrane.
The membranes were then blocked and incubated with anti–p-ERK1/2 followed by incubation with HRP-conjugated secondary antibody. The same
blots were then stripped and reprobed with ERK1/2 antibody. A representative blot from three experiments is shown here. B: The relative
intensities of p-ERK1/2:total ERK1/2 ratio quantitated by densitometry. Data are expressed as fold increase and are means  SEM from three
experiments. *P < 0.001 vs. 2.5 mmol/l glucose in the absence of GW-5074, **P < 0.001 vs. 20 mmol/l glucose in the absence of GW-5074. C: INS
832/13 cells were treated with either diluent alone or GW-5074 (10 mol/l) as indicated in the ﬁgure and cultured overnight in low-glucose media.
The cells were further incubated in the presence of either low (2.5 mmol/l) or high (20 mmol/l) glucose for 30 min at 37°C in the continuous
presence of either diluent alone or GW-5074. Insulin released into the medium was quantitated by ELISA. The data are expressed as percentage
of basal and are means  SEM from three independent experiments. *P < 0.05 vs. 2.5 mmol/l glucose alone, **P < 0.05 vs. 20 mmol/l glucose alone.
D: INS 832/13 cells were treated with either diluent alone or GW-5074 (10 mol/l) and cultured overnight in low-glucose media. The cells were
further incubated in the presence of either low glucose (2.5 mmol/l) or a membrane-depolarizing concentration of KCl (60 mmol/l; osmolality
adjusted by reducing NaCl in the incubation medium) for 45 min at 37°C in the continuous presence of either GW-5074 or diluent. Insulin released
into the medium was quantiﬁed using ELISA. Data are expressed as nanograms per milliliter of insulin released and are mean  SEM from eight
independent determinations. *P < 0.001 vs. respective low-glucose controls. E: INS-1 832/13 cells were transfected with mock, wild type, and
constitutively active Raf-1 (BXB) mutants at a ﬁnal concentration of 0.2 g of DNA and cultured overnight in low-glucose media. The cells were
further incubated in the presence of either low (2.5 mmol/l) or high (20 mmol/l) glucose for 30 min at 37°C. Protein lysates were then separated
by SDS-PAGE followed by transfer onto a nitrocellulose membrane. The membranes were then blocked and incubated with anti–p-ERK1/2
followed by incubation with HRP-conjugated secondary antibody. The same blots were then stripped and reprobed with ERK1/2 antibody. A
representative blot from three experiments is shown here. F: The relative intensities of p-ERK1/2:total ERK1/2 ratio quantitated by
densitometry. Data are expressed as fold increase over basal glucose and are means  SEM from three experiments. *P < 0.001 vs. 2.5 mmol/l
glucose-treated cells. G: INS-1 832/13 cells were transfected with mock, wild type, and constitutively active Raf-1 (BXB) mutants at a ﬁnal
concentration of 0.2 g of DNA and cultured overnight in low-glucose media. The cells were further incubated in the presence of either low (2.5
mmol/l) or high (20 mmol/l) glucose for 30 min at 37°C. Insulin released into the medium was quantitated by ELISA. Data are expressed as
percentage of basal and are means  SEM from three independent experiments. *P < 0.05 vs. 2.5 mmol/l glucose alone, **P < 0.05 vs. mock-,
vector-, or wild-type mutant–transfected cells treated with 20 mmol/l glucose.
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secretagogues, the majority of data appear to support
involvement of Raf-1 kinase in ERK1/2 activation. Our
current ﬁndings further conﬁrm the above observations
that Raf-1 kinase activation is necessary for glucose-
mediated effects on ERK1/2 phosphorylation. In addition,
they also implicate these signaling steps in glucose-in-
duced Rac1 activation and insulin secretion. Based on our
observations from H-Ras depletion experiments, it ap-
pears that H-Ras may not promote glucose-mediated ef-
fects on ERK1/2 activation and insulin secretion. These
studies are in agreement with ﬁndings of Briaud et al. on
lack of involvement of H-Ras on glucose-induced activa-
tion of ERK1/2 (25). The potential identity of the farnesy-
lated protein involved in glucose-mediated regulation of
ERK1/2, Rac1 activation, and insulin secretion remains to
be identiﬁed. In this context, it should be noted that, in
addition to Ras, speciﬁc forms of -subunits of trimeric
G-proteins (e.g., G1) undergo farnesylation. We previ-
ously reported immunologic identiﬁcation and carboxylm-
ethylation of G1,G 2,G 5, and G7 in pancreatic -cells,
which was stimulated by GTPS (in broken lysates) and
glucose, KCl, or Mas (in intact cells [43]). Because the
prenylation precedes the carboxylmethylation step, we
speculate that glucose-induced carboxylmethylation of G
subunit may, in part, be due to its ability to regulate
protein prenylation. This remains to be veriﬁed further.
It may be germane to point out that although there is a
general agreement that stimulatory concentrations of glu-
cose promote activation of ERK1/2 in pancreatic -cells,
potential roles of this signaling event(s) in GSIS remain
unclear. For example, studies by Khoo and Cobb demon-
strated that pharmacologic inhibition of ERK1/2 activation
had minimal effects on GSIS in INS-1 cells, suggesting that
ERK activation is not necessary for GSIS to occur (44).
Similar conclusions were drawn by Burns et al. in their
studies involving adult rodent islets (45). More recent
studies by Gray et al. (46) have suggested involvement of
ERK1/2 in signaling cascade leading to insulin secretion
after activation of the extracellular calcium-sensing recep-
tor. Using pharmacologic and molecular biological ap-
proaches, Longuet et al. (47) have demonstrated a pivotal
role of ERK1/2 in GSIS in MIN6 -cells. The underlying
reasons for such differential effects or roles for ERK1/2 in
GSIS remain unknown, but could be explained on the
basis of yet to be identiﬁed differences between -cell
preparations used in these studies. Our current ﬁndings in
INS 832/13 cells and normal rat islets provide evidence for
a direct regulatory role for ERK1/2 in GSIS, speciﬁcally at
the level of activation of Rac1, which has been implicated
FIG. 7. Inhibition of Raf-1 kinase or FTase markedly attenuates glucose-induced activation of Rac1 in INS 832/13 cells. INS 832/13 cells were
cultured overnight in low-serum, low-glucose media with either diluent alone or GW-5074 (10 mol/l) as indicated in the ﬁgure. The cells were
then incubated further (30 min) in the presence of either low (5 mmol/l) or high (20 mmol/l) glucose in the continuous presence of GW-5074 or
diluent. The degree of Rac1 activation was determined by PAK/PBD pull-down assay. A: A representative blot from four independent experiments
yielding similar results. B: Densitometric analysis of the ratio of total Rac1 and Rac1.GTP. Data are mean  SEM from four determinations in each
case. *P < 0.05 vs. diluent, **P < 0.05 vs. high glucose (20 mmol/l) alone and expressed as fold increase over basal. C: INS 832/13 cells were
cultured overnight in low-serum, low-glucose media with either diluent alone or FTI-277 (10 mol/l). The cells were then incubated further (30
min) in the presence of either low (2.5 mmol/l) or high (20 mmol/l) glucose in the continuous presence of FTI-277 or diluent. The degree of Rac1
activation was determined by PAK/PBD pull-down assay. Densitometric analysis of ratio of total Rac1 and Rac1.GTP. Data are mean  SEM from
two independent determinations in each case. *P < 0.05 vs. diluent, **P < 0.05 vs. high glucose (20 mmol/l) in the absence of FTI-277.
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exocytosis of insulin (8,14,23,31,42).
Our ﬁndings also implicate Raf-1 kinase activation as an
obligatory step for glucose-induced activation of Rac1 in
the pancreatic -cell. Potential connection between these
two signaling events remains unknown at this time. Along
these lines, Goalstone et al. (19) reported a signiﬁcant
stimulation of the phosphorylation of the -subunit of
FTase/GGTase-I leading to its functional activation and
farnesylation of Ras protein by insulin in 3T3-L1 ﬁbro-
blasts and adipocytes. Interestingly, insulin-stimulated
phosphorylation of the FTase/GGTase-I -subunit was
inhibited by PD98059, suggesting that FTase/GGTase-I
-subunit phosphorylation may be mediated by ERK ki-
nase. Further, increased phosphorylation of FTase/
GGTase-I -subunit in cells overexpressing the constitu-
tively active Raf-1 kinase mutant was also observed. Based
on these ﬁndings, these investigators concluded that insu-
lin-mediated activation involves a Ras/Raf-1/ERK signaling
pathway. Similar FTase activation mechanisms involving
phosphorylation of FTase -subunits have been proposed
during the transforming growth factor  receptor-1 activa-
tion (48). Our current ﬁndings are suggestive of such a
regulatory mechanism(s) for glucose-stimulated activation
of Rac1 as a consequence of Raf-1/ERK–mediated activa-
tion of the phosphorylation of the -subunit of FTase/
GGTase. This postulation is based on our recent ﬁndings
demonstrating a signiﬁcant inhibition in glucose-induced
activation and membrane association of Rac1 and insulin
secretion in INS 832/13 cells overexpressing a phosphory-
lation-deﬁcient dominant-negative mutant of FTase/
GGTase-I -subunit (23). Based on the data accrued in the
current investigations and evidence in the literature
(49), we propose that a farnesylation-sensitive Raf-1/
ERK1/2 signaling pathway is required for Rac1 activa-
tion leading to GSIS. Along these lines, using
recombinant substrates, we recently reported a signiﬁ-
cant stimulation (2.5- to 4.0-fold over basal) of FTase
and GGTase-I activities in INS 823/13 cells and rodent
islets (50). Potential involvement of ERK1/2 in the
phosphorylation and functional activation (19) of
FTase/GGTase-I by glucose remains to be determined.
It is important to note that our data accrued from the
overexpression of a constitutively active Raf-1 kinase
FIG. 8. Glucose-induced insulin secretion and Rac1 activation are markedly reduced in INS 832/13 cells after siRNA-mediated depletion of ERK1
and ERK2 expression. INS 832/13 cells were cultured in a 24-well plate overnight and transfected with ERK1 or ERK2 siRNA using HiPerfect
transfection reagent (see the RESEARCH DESIGN AND METHODS section for additional details). After 48 h, the cells were harvested and homogenized,
and 10 g protein was separated in 12% SDS-PAGE, transferred to membrane, and then probed with ERK1 (A) or ERK2 (B) antibody to determine
the efﬁciency of knockdown. Actin was used as reference protein. Mo, mock transfected; Sc, scrambled siRNA transfected. ERK1 or ERK2 siRNA
at 50 or 100 nmol/l. C: INS 832/13 cells were cultured in a 24-well plate overnight and transfected with either ERK1 (100 nmol/l) or ERK2 (100
nmol/l) or 50 nmol/l each of ERK1 and ERK2 siRNA. After 48 h, the cells were cultured overnight in low-glucose media followed by further
incubation with either low (2.5 mmol/l) or high (20 mmol/l) glucose for 45 min at 37°C. Insulin released into the medium was quantiﬁed using
ELISA. Data are expressed as nanograms per milliliter of insulin released and are mean  SEM from eight independent determinations. *P <
0.001 vs. low glucose, ** and ***P < 0.001 vs. high glucose-induced insulin release in scrambled siRNA-transfected cells. D: INS 832/13 cells were
cultured in a 24-well plate overnight and transfected with 50 nmol/l each of ERK1 and ERK2 siRNAs (as above). Glucose-induced activation of
Rac1 was determined by PAK/PBD pull-down assay (see the RESEARCH DESIGN AND METHODS section for additional details). Data are mean  SEM
from two pull-down assays. *P < 0.05 vs. low glucose, **P < 0.05 vs. Rac1 activation seen in the presence of high glucose (20 mmol/l) in scrambled
siRNA–transfected cells.
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activation while exerting a marked potentiation of GSIS in
INS 832/13 cells. Under these conditions, we failed to
detect any potentiating effects of this mutant on glucose-
induced Rac1 activation (i.e., 1.55  0.02-fold stimulation
by glucose in mock-transfected cells vs. 1.455  0.1-fold
stimulation by glucose in BXB-overexpressing cells; n  2
experiments). These data raise an interesting possibility
that additional (i.e., Raf-1/ERK1/2/Rac1 independent)
mechanisms might underlie the potentiating effects of BXB
on GSIS. These are being investigated in our laboratory
currently.
In conclusion, our current ﬁndings involving site-spe-
ciﬁc inhibitors of FTase (FTI-277 and FTI-2628) and FTase
siRNA provide direct evidence for the requirement for a
farnesylation step in glucose-induced ERK1/2 activation
and insulin secretion in pancreatic -cells. Using the above
approaches, we have also identiﬁed Rac1 as one of the
target G-proteins for Raf-1/ERK1/2, the activation of which
has been implicated in GSIS. The identity of the farnesy-
lated protein remains unknown, but appears to be different
from H-Ras because knockdown of H-Ras exerted minimal
effects on glucose-induced ERK1/2 activation and insulin
secretion. Studies are in progress to determine the identity
of the putative farnesylated protein, which is involved in
this regulatory pathway. Together, these ﬁndings support
our model that protein farnesylation–dependent Raf/ERK
signaling links to cytoskeletal remodeling and organization
to promote insulin secretion in -cells.
ACKNOWLEDGMENTS
This research was supported by a Merit Review Award
from the Department of Veterans Affairs (A.K.) and the
National Institutes of Health (DK-74921 [A.K.] and DK-
55267 [C.J.R.]). A.K. is also the recipient of the Senior
Research Career Scientist Award from the Department of
Veterans Affairs.
No potential conﬂicts of interest relevant to this article
were reported.
Parts of this study were presented at the 68th Scientiﬁc
Sessions of the American Diabetes Association, San Fran-
cisco, California, 6–10 June 2008.
REFERENCES
1. Prentki M, Matschinsky FM. Ca2, cAMP, and phospholipid-derived
messengers in coupling mechanisms of insulin secretion. Physiol Rev
1987;67:1185–1248
2. MacDonald MJ. Elusive proximal signals of beta-cells for insulin secretion.
Diabetes 1990;39:1461–1466
3. Newgard CB, McGarry JD. Metabolic coupling factors in pancreatic -cell
signal transduction. Annu Rev Biochem 1995;64:689–719
4. Poitout V. Phospholipid hydrolysis and insulin secretion: a step toward
solving the Rubik’s cube. Am J Physiol Endocrinol Metab 2008;294:E214–
E216
5. Jones PM, Persaud SJ. Protein kinases, protein phosphorylation, and the
regulation of insulin secretion from pancreatic -cells. Endocr Rev 1998;
19:429–461
6. Khoo S, Gibson TB, Arnette D, Lawrence M, January B, McGlynn K,
Vanderbilt CA, Griffen SC, German MS, Cobb MH. MAP kinases and their
roles in pancreatic beta-cells. Cell Biochem Biophys 2004;40(Suppl. 3):191–
200
7. Kowluru A. Identiﬁcation and characterization of a novel protein histidine
kinase in the islet beta cell: evidence for its regulation by mastoparan, an
activator of G-proteins and insulin secretion. Biochem Pharmacol 2002;63:
2091–2100
8. Wang Z, Thurmond DC. Mechanisms of biphasic insulin-granule exocyto-
sis: roles of the cytoskeleton, small GTPases and SNARE proteins. J Cell
Sci 2009;122:893–903
9. Bokoch GM. Biology of the p21-activated kinases. Annu Rev Biochem
2003;72:743–781
10. Chong H, Vikis HG, Guan KL. Mechanisms of regulating the Raf kinase
family. Cell Signal 2003;15:463–469
11. Baccarini M. Second nature: biological functions of the Raf-1 “kinase.”
FEBS Lett 2005;579:3271–3277
12. DerMardirossian CM, Bokoch GM. Phosphorylation of RhoGDI by p21-
activated kinase 1. Methods Enzymol 2006;406:80–90
13. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev
2001;81:153–208
14. Kowluru A. Small G-proteins in islet beta-cell function. Endocr Rev
2010;31:52–78
15. Kowluru A. Protein prenylation in glucose-induced insulin secretion from
the pancreatic islet beta cell: a perspective. J Cell Mol Med 2008;12:164–
173
16. Casey PJ, Seabra MC. Protein prenyltransferases. J Biol Chem 1996;271:
5289–5292
17. Seabra MC, Reiss Y, Casey PJ, Brown MS, Goldstein JL. Protein farnesyl-
transferase and geranylgeranyltransferase share a common alpha subunit.
Cell 1991;65:429–434
18. Fu HW, Casey PJ. Enzymology and biology of CaaX protein prenylation.
Rec Prog Horm Res 1999;54:315–342; discussion 342–343
19. Goalstone M, Carel K, Leitner JW, Draznin B. Insulin stimulates the
phosphorylation and activity of farnesyltransferase via the Ras-mitogen-
activated protein kinase pathway. Endocrinology 1997;138:5119–5124
20. Li G, Regazzi R, Roche E, Wollheim CB. Blockade of mevalonate produc-
tion by lovastatin attenuates bombesin and vasopressin potentiation of
nutrient-induced insulin secretion in HIT-T15 cells: probable involvement
of small GTP-binding proteins. Biochem J 1993;289:379–385
21. Metz SA, Rabaglia ME, Stock JB, Kowluru A. Modulation of insulin
secretion from normal rat islets by inhibitors of the post-translational
modiﬁcations of GTP-binding proteins. Biochem J 1993;295:31–40
22. Amin R, Chen HQ, Tannous M, Gibbs R, Kowluru A. Inhibition of glucose-
and calcium-induced insulin secretion from betaTC3 cells by novel inhib-
itors of protein isoprenylation. J Pharmacol Exp Ther 2002;303:82–88
23. Veluthakal R, Kaur H, Goalstone M, Kowluru A. Dominant-negative alpha-
subunit of farnesyl- and geranylgeranyltransferase inhibits glucose-stimu-
lated, but not KCl-stimulated, insulin secretion in INS 832/13 cells.
Diabetes 2007;56:204–210
24. Ehses JA, Pelech SL, Pederson RA, McIntosh CH. Glucose-dependent
insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a
cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway.
J Biol Chem 2002;277:37088–37097
25. Briaud I, Lingohr MK, Dickson LM, Wrede CE, Rhodes CJ. Differential
activation mechanisms of Erk-1/2 and p70(S6K) by glucose in pancreatic
beta-cells. Diabetes 2003;52:974–983
26. Tru ¨mper J, Ross D, Jahr H, Brendel MD, Go ¨k eR ,H o ¨rsch D. The Rap-B-Raf
signalling pathway is activated by glucose and glucagon-like peptide-1 in
human islet cells. Diabetologia 2005;48:1534–1540
27. Gomez E, Pritchard C, Herbert TP. cAMP-dependent protein kinase and
Ca
2 inﬂux through L-type voltage-gated calcium channels mediate Raf-
independent activation of extracellular regulated kinase in response to
glucagon-like peptide-1 in pancreatic beta-cells. J Biol Chem 2002;277:
48146–48151
28. Raman M, Chen W, Cobb MH. Differential regulation and properties of
MAPKs. Oncogene 2007;26:3100–3112
29. Veluthakal R, Madathilparambil SV, McDonald P, Olson LK, Kowluru A.
Regulatory roles of Tiam1, a guanine nucleotide exchange factor for Rac1,
in glucose-stimulated insulin secretion in pancreatic beta-cells. Biochem
Pharmacol 2009;77:101–113
30. Kowluru A, Seavey SE, Li G, Sorenson RL, Weinhaus AJ, Nesher R,
Rabaglia ME, Vadakekalam J, Metz SA. Glucose- and GTP-dependent
stimulation of the carboxylmethylation of Cdc42 in rodent and human
pancreatic islets and pure beta cells: evidence for an essential role for
GTP-binding proteins in nutrient-induced insulin secretion. J Clin Invest
1996;98:540–555
31. Li J, Luo R, Kowluru A, Li G. Novel regulation by Rac1 of glucose- and
forskolin-induced insulin secretion in INS-1 beta-cells. Am J Physiol
Endocrinol Metab 2004;286:E818–E827
32. Higashijima T, Uzu S, Nakajima T, Ross EM. Mastoparan, a peptide toxin
from wasp venom, mimics receptors by activating GTP-binding proteins (G
proteins). J Biol Chem 1988;263:6491–6494
33. Straub SG, James RF, Dunne MJ, Sharp GW. Glucose augmentation of
mastoparan-stimulated insulin secretion in rat and human pancreatic
islets. Diabetes 1998;47:1053–1057
34. Daniel S, Noda M, Cerione RA, Sharp GW. A link between Cdc42 and
FARNESYLATION IN INSULIN SECRETION
976 DIABETES, VOL. 59, APRIL 2010 diabetes.diabetesjournals.orgsyntaxin is involved in mastoparan-stimulated insulin release. Biochemis-
try 2002;41:9663–9671
35. Amin RH, Chen HQ, Veluthakal R, Silver RB, Li J, Li G, Kowluru A.
Mastoparan-induced insulin secretion from insulin-secreting betaTC3 and
INS-1 cells: evidence for its regulation by Rho subfamily of G proteins.
Endocrinology 2003;144:4508–4518
36. Jones PM, Mann FM, Persaud SJ, Wheeler-Jones CP. Mastoparan stimu-
lates insulin secretion from pancreatic beta-cells by effects at a late stage
in the secretory pathway. Mol Cell Endocrinol 1993;94:97–103
37. Lawrence M, Shao C, Duan L, McGlynn K, Cobb MH. The protein kinases
ERK1/2 and their roles in pancreatic beta cells. Acta Physiol (Oxf)
2008;192:11–17
38. Khoo S, Griffen SC, Xia Y, Baer RJ, German MS, Cobb MH. Regulation of
insulin gene transcription by ERK1 and ERK2 in pancreatic beta cells.
J Biol Chem 2003;278:32969–32977
39. Arnette D, Gibson TB, Lawrence MC, January B, Khoo S, McGlynn K,
Vanderbilt CA, Cobb MH. Regulation of ERK1 and ERK2 by glucose and
peptide hormones in pancreatic beta cells. J Biol Chem 2003;278:32517–
32525
40. Gibson TB, Lawrence MC, Gibson CJ, Vanderbilt CA, McGlynn K, Arnette
D, Chen W, Collins J, Naziruddin B, Levy MF, Ehrlich BE, Cobb MH.
Inhibition of glucose-stimulated activation of extracellular signal-regulated
protein kinase 1 and 2 by epinephrine in pancreatic beta-cells. Diabetes
2006;55:1066–1073
41. Fro ¨din M, Sekine N, Roche E, Filloux C, Prentki M, Wollheim CB, Van
Obberghen E. Glucose, other secretagogues, and nerve growth factor
stimulate mitogen-activated protein kinase in the insulin-secreting beta-
cell line, INS-1. J Biol Chem 1995;270:7882–7889
42. Kowluru A, Veluthakal R. Rho guanosine diphosphate-dissociation inhibi-
tor plays a negative modulatory role in glucose-stimulated insulin secre-
tion. Diabetes 2005;54:3523–3529
43. Kowluru A, Li G, Metz SA. Glucose activates the carboxyl methylation of
gamma subunits of trimeric GTP-binding proteins in pancreatic beta cells.
Modulation in vivo by calcium, GTP, and pertussis toxin. J Clin Invest
1997;100:1596–1610
44. Khoo S, Cobb MH. Activation of mitogen-activating protein kinase by
glucose is not required for insulin secretion. Proc Natl Acad SciUSA
1997;94:5599–5604
45. Burns CJ, Howell SL, Jones PM, Persaud SJ. Glucose-stimulated insulin
secretion from rat islets of Langerhans is independent of mitogen-activated
protein kinase activation. Biochem Biophys Res Commun 1997;239:447–
450
46. Gray E, Muller D, Squires PE, Asare-Anane H, Huang GC, Amiel S, Persaud
SJ, Jones PM. Activation of the extracellular calcium-sensing receptor
initiates insulin secretion from human islets of Langerhans: involvement of
protein kinases. J Endocrinol 2006;190:703–710
47. Longuet C, Broca C, Costes S, Hani EH, Bataille D, Dalle S. Extracellularly
regulated kinases 1/2 (p44/42 mitogen-activated protein kinases) phos-
phorylate synapsin I and regulate insulin secretion in the MIN6 beta-cell
line and islets of Langerhans. Endocrinology 2005;146:643–654
48. Kawabata M, Imamura T, Miyazono K, Engel ME, Moses HL. Interaction of
the transforming growth factor-beta type I receptor with farnesyl-protein
transferase-alpha. J Biol Chem 1995;270:29628–29631
49. Wang T, Danielson PD, Li BY, Shah PC, Kim SD, Donahoe PK. The
p21(RAS) farnesyltransferase alpha subunit in TGF-beta and activin sig-
naling. Science 1996;271:1120–1122
50. Goalstone M, Kamath V, Kowluru A. Glucose activates prenyltransferases
in pancreatic islet beta-cells. Biochem Biophys Res Commun 2010;391:
895–898
A. KOWLURU AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, APRIL 2010 977